Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 6/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.61 |
| ▸ | PRKD2 | Q9BZL6 | 5/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.61 |
| ▸ | MINK1 | Q8N4C8 | 4/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.61 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.61 |
| ▸ | CAMK2B | Q13554 | 3/20 | 0.61 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.61 |
| ▸ | PIM1 | P11309 | 3/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.61 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.61 |
| ▸ | CAMK2G | Q13555 | 2/20 | 0.61 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.61 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.61 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989903 | 0.94 | ERBB2 (0.55) | CSNK1DMAPK9PRKD2ERBB2MAPK8 | |
| SCHEMBL5770544 | 0.79 | MAPK14 (0.61) | CSNK1DMAPK9PRKD2ERBB2MAPK8 | |
| SCHEMBL990057 | 0.77 | MAPK14 (0.67) | CSNK1DMAPK9PRKD2ERBB2MAPK8 | |
| SCHEMBL13143881 | 0.76 | MAPK8 (1.00) | CSNK1DMAPK9PRKD2ERBB2MAPK8 | |
| SCHEMBL9436258 | 0.74 | TGFBR1 (0.69) | CSNK1DTGFBR1TGFBR2MAPK14CSNK1E | |
| SCHEMBL17767553 | 0.73 | TGFBR1 (0.59) | CSNK1DTGFBR1TGFBR2MAPK14CSNK1E | |
| SCHEMBL17767421 | 0.73 | MAPK14 (0.56) | CSNK1DMAPK9PRKD2ERBB2MAPK8 | |
| SCHEMBL990878 | 0.72 | MAPK14 (0.68) | CSNK1DMAPK9PRKD2ERBB2MAPK8 | |
| SCHEMBL990260 | 0.71 | ERBB2 (0.55) | CSNK1DMAPK9PRKD2ERBB2MAPK8 | |
| SCHEMBL5772307 | 0.70 | MAPK14 (0.55) | CSNK1DMAPK9PRKD2ERBB2MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207531-B | Fused imidazole derivatives as TGF-beta inhibitors | 里格尔药品股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-12-06 | — | — | US | disclosed |
| EP-3221318-A1 | FUSED IMIDAZOLE DERIVATIVES AS TGF-BETA INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016081364-A1 | FUSED IMIDAZOLE DERIVATIVES AS TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-26 | — | — | WO | disclosed |
| US-7863310-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080227839-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-09-18 | — | — | US | disclosed |
| EP-1720862-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005080380-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | TGFBR1, TGFBR2, SMAD3 | CSNK1D 417/4885MAPK9 664/4885PRKD2 3081/4885 |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | TGFBR1, TGFBR2, SMAD3 | CSNK1D 417/4885MAPK9 664/4885PRKD2 3081/4885 |
| US-20080227839-A1 | Kinase Inhibitors | ABL1, MAP3K20, MAP3K19 | CSNK1D 85/4885MAPK9 140/4885PRKD2 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.